U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07419334) titled 'Phase 3 Study of the Safety, Tolerability, and Efficacy of ALK-001 on the Progression of Stargardt Disease' on Feb. 10.
Brief Summary: This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Stargardt Disease
Intervention:
DRUG: ALK-001
Daily oral administration for 24 months
DRUG: Placebo
Daily oral administration for 24 months
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Alkeus Pharmaceuticals, Inc.
Publ...